ELPEN is the leading Greek pharmaceutical company. With more than 850 employees, the company ranks 6th among more than 400 companies in the Greek market, with an annual turnover of €150 million (IMS data). ELPEN has been active in export activities since 1990, with an international presence in more than 60 countries worldwide and a subsidiary in Berlin, Germany, since 2009. We specialize in branded generics and originator products in CVS, CNS, respiratory, oncology and antimicrobials. Elpen’s activities include product development, production, regulatory affairs, marketing, sales, and exports. R&D is performed in 1.000m2 facilities focusing on cardiology, endocrinology, cancer, respiratory diseases and OTC. Examples of R&D activities include the Elpenhaler® DPI products already introduced in the EU markets, such as Formopen® (formoterol), Fluticapen® (fluticasone) and Rolenium® (salmeterol/fluticasone combination). We possess full production lines of Oral Solids, Oral Liquids, Dry Powder Inhalation, Injectable, Lyophilized products and a dedicated facility for the production of Oral Solid Penicillin.